Biological and Pathological Study of Prostate Cancer at Localized Stage in Western Algeria

• Abdelkrim Berroukche

  Department of Biology, Faculty of Sciences and Technology, Moulay Tahar University of Saida, Algeria

• Malika Bendahmane-Salmi

  Department of Biology, Faculty of Sciences, Djillali Liabes University of Sidi-Bel-Abbes, Algeria

• Badreddine Abdelkrim Kandouci

  Research Laboratory of Environment and Health (RLEH), Faculty of Medicine, University Hospital of Sidi-Bel-Abbes, Algeria

 Objective:Toshow the contribution of the pathological examination, associated with prostatic specific antigen (PSA), in the early detection of prostate cancer in Western Algeria.

Methodology:This study focused on 160 cases, old between 50-80 years, with histologically confirmed prostate adenocarcinoma and carried out in urology hospitals in western Algeria during the period from 2007 to 2011. Tumor stage, PSA, Gleason score and the degree of tumor differentiation were analyzed.

Results:135 patients, with a poor prognosis and a Gleason score > 8 index of incurable malignant aggression, have not been the subject of this study. But the other 35 patients were candidates because they had a favorable prognosis with a localized stage that could be curable. Gleason score was between 5-6 in 5 patients with TPSA  10 ng / ml at differential stage, score of 7 in 10 patients with TPSA between 10-20 ng / ml atmoderately differentiated stage and finally a score of 8 in 20 patients with TPSA between 20,1-50 ng / ml at apoorly differentiated stage.

Conclusion:There is a strong correlation between TPSA, Gleason score and the degree of tumor differentiation. Biological and pathological prognosis, established early, can reduce tumor progression.

Grosclaude P. Evolution de l’incidence et de la mortalité par cancer en France de 1978 à 2000. Prostate 2003; Invs.sante.fr.

Berroukche A, Bendahmane M, Kandouci BA. Performance du dosage de PSA dans le dépistage précoce du cancer de la prostate. Etude cas-témoins dans un hôpital de l’Ouest Algérien. Immuno-analyse et biologie spécialisée 2012; 27: 54-60. http://dx.doi.org/10.1016/j.immbio.2012.01.010

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10, http://globocan.iarc.fr.

Shannon BA, McNeal JE, Cohen RJ. Transition zone carcinoma of the prostate gland: a common indolent tumour type that occasionally manifests aggressive behaviour. Pathology 2003; 35(6): 467-71. http://dx.doi.org/10.1080/00313020310001619154

Castanho MJP, Barros LC. Prognostico de Cancer de Prostata: Probabilidade e Possibilidade. Mat Apl Comput 2007; 8(3): 371-79.

Rigaud J, Tiguert R, Fradet Y, Bouchot O. Salvage radical prostatectomy after radiotherapy failure in localized prostatic cancer. Prog Urol 2002; 12(6): 1179-87.

Tiguert R, Ravery V, Grignon DJ, Sakr W, Wood DP, Edson Pontes J. Le grade principal du score 7 de Gleason de la pièce opératoire corrélé à la progression biologique des patients traités par prostatectomie totale. Prog Urol 2002; 12: 31-36.

Stamey TA, Yemoto CM, McNeal JE, Sigal BM, Johnstone IM. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol 2000; 163(4): 1155-60. http://dx.doi.org/10.1016/S0022-5347(05)67713-0

Mariano MB, Tefilli MV, Fonseca GN, Goldraich IH. Laparoscopic radical prostatectomy: 10 years experience. Int Braz J Urol 2009; 35(5): 565-71. http://dx.doi.org/10.1590/S1677-55382009000500008

Tefilli MV, Gheiler EL, Tiguert R, et al. Role of radical prostatectomy in patients with prostate cancer of highGleason score. Prostate 1999; 39: 60-66. http://dx.doi.org/10.1002/(SICI)1097-0045(19990401)39:1<60::AID-PROS10>3.0.CO;2-U

Fendler JPH, Dujardin T, Bringeon G, Adeleine P, Devonec M, Perrin P. Progression après prostatectomie radicale pour cancer de la prostate: critères pronostiques et place du PSA dans la surveillance. Prog Urol 1992; 2: 58-65.

Blute M, Lau W, Sebo T, Zincke H. Prognostic factors forsurvival in patients with pathological Gleason 7 prostate. Is there adifference in outcome between Gleason 3+4 versus 4+3. J Urol 2000; 163: 320.

Chan TY, Partin AW, Walsh PC, Epstein JI. Prognostic significance of Gleason 4+3 tumor at radical prostatectomy. J Urol 2000; 163: 320.

Ukimura O, Coleman JA, de la Taille, et al. Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol 2013; 63 (2): 214-30. http://dx.doi.org/10.1016/j.eururo.2012.09.033

Ravery V, Toublanc M, Hermieu JF, Boccon-Gibod L. Specimen gleason score 7 with predomi-nant grade 4 adversely impact on outcome after radical prostatecto-my. Eur Urol 2000; 37: 394.

Sakr WA, Tefilli MV, Grignon DJ Jr., et al. Gleason 7 score prostate cancer: A heterogenous entity? Correlation with pathologic parameters and disease free survival. J Urol 2000; 161: 243.

Varma M, Berney DM, Algaba F, et al. Prostate needle biopsy processing: a survey of laboratory practice across Europe. J Clin Pathol 2013; 66(2): 120-3. http://dx.doi.org/10.1136/jclinpath-2012-200993

Miller GJ, Brawer MK, Sakr WA, Thrasher JB, Townsend R. Prostate cancer: serum and tissue markers. Rev Urol 2001; 3(2): 11-9.

• PDF